Nystagmus Market Research Report–Global Forecast till 2023

Nystagmus Market Share And Application By Type (Infantile, Latent Nystagmus, Noonan Syndrome, Nystagmus Blockage Syndrome) Diagnosis (Ct Scan, Mr Scan, Chromosome Analysis, Ultrasonography) Treatment (Medication, Surgical) End-User – Global Forecast Till 2023

ID: MRFR/Pharma/3995-HCR | February 2021 | Region: Global | 110 pages

Market Scenario:


Nystagmus is a vision associated medical condition, characterized by repetitive and uncontrolled movements of the eye. These movements often result in reduced vision and can further affect the balance and coordination of the body. Fatigue and stress worsen the prognosis of nystagmus. However, the exact cause for the condition is still unknown. The major causes of nystagmus identified include congenital neurological problem or neurological disorders developed in early childhood. Other causes of nystagmus include lack of development of normal eye movement in early life, refractive error, for example, near-sightedness (myopia) or astigmatism, inflammation of the inner ear, medications such as anti-epilepsy drugs, and central nervous system diseases among others


The nystagmus market growth is majorly attributed to the increasing prevalence of the genetic and eye related disorders. Moreover, increasing mental retardation and neurological abnormalities will drive the market growth.


According to the World Health Organization (WHO), an estimated 253 million people live with vision impairment, 36 million are blind, and 217 million have moderate to severe vision impairment worldwide. An estimated 19 million children (below age 15) are vision impaired.


According to the WHO estimates, neurological abnormalities are responsible for 4.5%-11% of all illnesses in the low or high-income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.


However, availability of expensive treatment and poor reimbursement policies in the developing regions of the world are some of the factors, which may hamper the market growth during the forecast period.


The global nystagmus market is expected to grow at a CAGR of approximately 6.2% during the forecast period, 2017-2023.
Global Nystagmus Market, by region 2016(%)


 global nystagmus


Intended Audience:



  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Research Methodology:


  nystagmus


Sources: Annual reports, Press release, White paper, and Company presentation


Segmentation:


The nystagmus is segmented on the basis of type, diagnosis, treatment, and end-users.


Based on the type, the market is segmented into infantile, latent nystagmus, noonan syndrome, and nystagmus blockage syndrome.


On the basis of the diagnosis, the market is segmented into CT scan, MR scan, chromosome analysis, ultrasonography, and others.


On the basis of the treatment, the market is segmented into medications, surgical, and others.


On the basis of the end-user, the market is segmented into hospitals & clinics, research centers, specialty eye clinics, and others.


Regional Analysis:


The global nystagmus market consists of countries namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.


The Americas dominate the global nystagmus market owing to well-developed technology, increasing number of patients with eye-related problems, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies in the region have fuelled the growth of the market in this region.  


Europe holds the second position in the global nystagmus market owing to the government support for research & development and availability of funds for research. Moreover, this is expected to continue to drive the European market over the forecasted period. For instance, countries like Germany and France are increasing their investments in the healthcare domain.     


Asia Pacific is the fastest growing nystagmus market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods for eye diseases in countries like India and South Korea is likely to emerge as the fastest growing market across the globe. Furthermore, growing demand for quality devices in the healthcare sector is projected to lead the use of advanced equipment, which, in turn, will increase the market growth of nystagmus in the region.  


On the other hand, in the Middle East and Africa, eye problems have become a huge issue due to limited screening, ignorance of diseases, and poor access to treatment.


Key Players:


Some of key the players in the global nystagmus market are Bristol-Myers Squibb Company, NUSAPURE, ALLERGAN, Aerie Pharmaceuticals, Inc., Pfizer Inc., Valeant Pharmaceuticals International, Inc., Bayer AG, Genentech, Inc., Novartis AG , Regeneron Pharmaceuticals, Inc., Shire, and Santen Pharmaceutical Co., Ltd., and others.



Frequently Asked Questions (FAQ) :


Nystagmus market is expected to exhibit a CAGR of 6.2% from 2017 to 2023.

Nystagmus market is driven by the high prevalence of genetic and eye disorders.

Lack of effective reimbursement schemes and offering of expensive treatment can hamper the global nystagmus market growth.

The Americas can be dominant in the global nystagmus market till 2023.

Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Bayer AG, NUSAPURE, ALLERGAN, Novartis AG, Genentech, Inc., Aerie Pharmaceuticals, Inc., Pfizer Inc., Shire, Bristol-Myers Squibb Company, and Valeant Pharmaceuticals International, Inc. are key players of the global nystagmus market.

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Nystagmus Market, by Type

6.1 Introduction

6.2 Infantile

6.2.1 Market Estimates & Forecast, 2017-2023

6.3 Latent Nystagmus

6.3.1 Market Estimates & Forecast, 2017-2023

6.4 Noonan Syndrome

6.4.1 Market Estimates & Forecast, 2017-2023

6.5 Nystagmus Blockage Syndrome

6.5.1 Market Estimates & Forecast, 2017-2023

7. Global Nystagmus Market, by Diagnosis

7.1 Introduction

7.2 CT scan

7.2.1 Market Estimates & Forecast, 2017-2023

7.3 MR scan

7.3.1 Market Estimates & Forecast, 2017-2023

7.4 Others

7.4.1 Market Estimates & Forecast, 2017-2023

8. Global Nystagmus Market, by Treatment

8.1 Introduction

8.2 Medication

8.2.1 Market Estimates & Forecast, 2017-2023

8.3 Surgery

8.3.1 Market Estimates & Forecast, 2017-2023

9. Global Nystagmus Market, by End User

9.1 Introduction

9.2 Hospitals & Clinics

9.2.1 Market Estimates & Forecast, 2017-2023

9.3 Research Centers

9.3.1 Market Estimates & Forecast, 2017-2023

9.4 Others

9.4.1 Market Estimates & Forecast, 2017-2023

10. Global Nystagmus Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 UK

10.3.1.4 Italy

10.3.1.5 Spain

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

12 Company Profiles

12.1 Bristol-Myers Squibb Company

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 NUSAPURE

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 ALLERGAN

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Aerie Pharmaceuticals, Inc.

12.4.1 Company Overview

12.4.2 Product/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Pfizer Inc.

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 Valeant Pharmaceuticals International, Inc

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 Bayer AG

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Others

13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Pharmaceutical Industry

14 Appendix

LIST OF TABLES

Table 1 Nystagmus Industry Synopsis, 2017-2023

Table 2 Global Nystagmus Market Estimates and Forecast, 2017-2023, (USD Million)

Table 3 Global Nystagmus Market by Region, 2017-2023, (USD Million)

Table 4 Global Nystagmus Market by Types, 2017-2023, (USD Million)

Table 5 Global Nystagmus Market by Diagnosis, 2017-2023, (USD Million)

Table 6 Global Nystagmus Market by Treatment, 2017-2023, (USD Million)

Table 7 Global Nystagmus Market by End Users, 2017-2023, (USD Million)

Table 8 North America Nystagmus Market by Types, 2017-2023, (USD Million)

Table 9 North America Nystagmus Market by Diagnosis, 2017-2023, (USD Million)

Table 10 North America Nystagmus Market by Treatment, 2017-2023, (USD Million)

Table 11 North America Nystagmus Market by End Users, 2017-2023, (USD Million)

Table 12 US Nystagmus Market by Types, 2017-2023, (USD Million)

Table 13 US Nystagmus Market by Diagnosis, 2017-2023, (USD Million)

Table 14 US Nystagmus Market by Treatment, 2017-2023, (USD Million)

Table 15 US Nystagmus Market by End Users, 2017-2023, (USD Million)

Table 16 Canada Nystagmus Market by Types, 2017-2023, (USD Million)

Table 17 Canada Nystagmus Market by Diagnosis, 2017-2023, (USD Million)

Table 18 Canada Nystagmus Market by Treatment, 2017-2023, (USD Million)

Table 19 Canada Nystagmus Market by End Users, 2017-2023, (USD Million)

Table 20 South America Nystagmus Market by Types, 2017-2023, (USD Million)

Table 21 South America Nystagmus Market by Diagnosis, 2017-2023, (USD Million)

Table 22 South America Nystagmus Market by Treatment, 2017-2023, (USD Million)

Table 23 South America Nystagmus Market by End Users, 2017-2023, (USD Million)

Table 24 Europe Nystagmus Market by Types, 2017-2023, (USD Million)

Table 25 Europe Nystagmus Market by Diagnosis, 2017-2023, (USD Million)

Table 26 Europe Nystagmus Market by Treatment, 2017-2023, (USD Million)

Table 27 Europe Nystagmus Market by End Users, 2017-2023, (USD Million)

Table 28 Western Europe Nystagmus Market by Types, 2017-2023, (USD Million)

Table 29 Western Europe Nystagmus Market by Diagnosis, 2017-2023, (USD Million)

Table 30 Western Europe Nystagmus Market by Treatment, 2017-2023, (USD Million)

Table 31 Western Europe Nystagmus Market by End Users, 2017-2023, (USD Million)

Table 32 Eastern Europe Nystagmus Market by Types, 2017-2023, (USD Million)

Table 33 Eastern Europe Nystagmus Market by Diagnosis, 2017-2023, (USD Million)

Table 34 Eastern Europe Nystagmus Market by Treatment, 2017-2023, (USD Million)

Table 35 Eastern Europe Nystagmus Market by End Users, 2017-2023, (USD Million)

Table 36 Asia Pacific Nystagmus Market by Types, 2017-2023, (USD Million)

Table 37 Asia Pacific Nystagmus Market by Diagnosis, 2017-2023, (USD Million)

Table 38 Asia Pacific Nystagmus Market by Treatment, 2017-2023, (USD Million)

Table 39 Asia Pacific Nystagmus Market by End Users, 2017-2023, (USD Million)

Table 40 Middle East & Africa Nystagmus Market by Types, 2017-2023, (USD Million)

Table 41 Middle East & Africa Nystagmus Market by Diagnosis, 2017-2023, (USD Million)

Table 42 Middle East & Africa Nystagmus Market by Treatment, 2017-2023, (USD Million)

Table 43 Middle East & Africa Nystagmus Market by End Users, 2017-2023, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Nystagmus Market

Figure 3 Segmentation Market Dynamics for Nystagmus Market

Figure 4 Global Nystagmus Market Share, by Diagnosis 2016

Figure 5 Global Nystagmus Market Share, by Treatment 2016

Figure 6 Global Nystagmus Market Share, by End Users, 2016

Figure 7 Global Nystagmus Market Share, by Region, 2016

Figure 8 North America Nystagmus Market Share, by Country, 2016

Figure 9 Europe Nystagmus Market Share, by Country, 2016

Figure 10 Asia Pacific Nystagmus Market Share, by Country, 2016

Figure 11 Middle East & Africa Nystagmus Market Share, by Country, 2016

Figure 12 Global Nystagmus Market: Company Share Analysis, 2016 (%)

Figure 13 Bristol-Myers Squibb Company: Key Financials

Figure 14 Bristol-Myers Squibb Company: Segmental Revenue

Figure 16 Bristol-Myers Squibb Company: Geographical Revenue

Figure 17 NUSAPURE: Key Financials

Figure 18 NUSAPURE: Segmental Revenue

Figure 19 NUSAPURE: Geographical Revenue

Figure 20 ALLERGAN: Key Financials

Figure 21 ALLERGAN: Segmental Revenue

Figure 22 ALLERGAN: Geographical Revenue

Figure 23 Aerie Pharmaceuticals, Inc: Key Financials

Figure 24 Aerie Pharmaceuticals, Inc: Segmental Revenue

Figure 25 Aerie Pharmaceuticals, Inc: Geographical Revenue

Figure 26 Pfizer Inc: Key Financials

Figure 27 Pfizer Inc: Segmental Revenue

Figure 28 Pfizer Inc: Geographical Revenue

Figure 29 Valeant Pharmaceuticals International, Inc.: Key Financials

Figure 30 Valeant Pharmaceuticals International, Inc.: Segmental Revenue

Figure 31 Valeant Pharmaceuticals International, Inc.: Geographical Revenue

Figure 32 Bayer AG: Key Financials

Figure 33 Bayer AG: Segmental Revenue

Figure 34 Bayer AG: Geographical Revenue